Join
Live feed
·
PRReleasevia Quantisnow
FibroBiologics Inc. logo

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

ByQuantisnow·Wall Street's wire, on your screen.
FBLG· FibroBiologics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBLG (FibroBiologics Inc.) and more on Quantisnow.